|
|
![horizontal rule](https://webarchive.library.unt.edu/eot2008/20081004033909im_/http://www.fda.gov/graphics/blkpixel.gif) |
Congressional
Testimony
|
|
![](https://webarchive.library.unt.edu/eot2008/20081004033909im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
|
|
|
|
![](https://webarchive.library.unt.edu/eot2008/20081004033909im_/http://www.fda.gov/graphics/dot_clear.gif) |
1999
November
- William Raub, Ph.D., November
9, 1999
Deputy Assistant Secretary for Science Policy, Department
of Health and Human Services before the Subcommittee on National
Security, Veterans' Affairs, discuss Federal policies governing
the administration of investigational new drugs to U.S. military
personnel, including the safeguards and protections recently
announced in the Executive Order 13139 issued by the President.
October
- William K. Hubbard, October 28,
1999
Senior Associate Commissioner for Policy, Planning and Legislation,
Food and Drug Administration before the Subcommittee on Oversight
and Investigations Committee on Veterans' Affairs, to provide
an update on FDA's efforts to validate our optimism as the
year 2000 draws near.
- William K. Hubbard, October 21,
1999
Senior Associate Commissioner for Policy, Planning and Legislation,
Food and Drug Administration before the House Committee on
Commerce Subcommittee on Health and Environment, to provide
an update on the Year 2000 (Y2K) date issue as it relates
to medical devices, drugs and biologics.
- Jane E. Henney, M.D.,October
21, 1999
Commissioner of Food and Drugs of the Food and Drug Administration
before the Committee on Health, Education, Labor and Pensions,
on the Agency's progress on its implementation of the Food
and Drug Administration Modernization Act of 1997 (FDAMA or
Modernization Act).
- James H. Maryanski Ph.D.,October
19, 1999
Biotechnology Coordinator, CFSAN of Food and Drug Administration
before the Committee on Science Subcommitee in Basic ResearchForestry,
on regulatory program for foods derived from new plant varieties,
including genetically engineered varieties.
- Kathryn C. Zoon, Ph.D.,October
12, 1999
Director, Center for Biologics Evaluation and Research of
the Food and Drug Administration before the Committee on Government
Reform to discuss vaccine licensing generally, and specifically,
the safety and efficacy of the anthrax vaccine.
- James H. Maryanski Ph.D.,October
7, 1999
Biotechnology Coordinator, CFSAN of Food and Drug Administration
before the Senate Committee on Agriculture, Nurition and Forestry,
on regulatory program for foods derived from new plant varieties,
including genetically engineered varieties.
September
- Jane Henney, M.D., August
4, 1999
Commissioner of Food and Drug Administration before the Senate
Governmental Affairs Committee, on behalf of the President's
Council of Food Safety.
July
- Jane Woodcock, M.D., July
30, 1999
Director, Center for Drug Evaluation and Research of the Food
and Drug Administration before the Subcommittee on Oversight
and Investigations, on the benefits and risks of pharmaceutical
sales over the Internet.
- Susan S. Ellenberg, Ph.D.,
July 21, 1999
Director, Division of Biostatistics and Epidemiology,CBER
of the Food and Drug Administration before the subcommittee
on National Security, Veterans Affairs and International Relations,
FDA's Vaccine Adverse Event Reporting System (VAERS) and its
interface with the Department of Defense's (DOD) Anthrax Vaccine
Immunization Program (AVIP).
- Morris E. Potter, July 1,
1999
Director of Food Safety Initiatives,CFSAN of the Food and
Drug Administration before the subcommittee on Government
Management, Restructuring, and the District of Columbia to
testify on the Federal role in the oversight of egg safety
and the related General Accounting Office's (GAO) report.
May
- Joseph A. Levitt, May 27, 1999
Director, Center for Food Safety and Applied Nutrition of
the Food and Drug Administration before the Committee on Government
Reform to discuss FDA's adverse event reporting systems, particularly
the system for monitoring special nutritional products, including
dietary supplements.
- William K. Hubbard, May 25,
1999
Acting Deputy Commissioner for Policy of the Food and Drug
Administration before the Subcommittee on Oversight and Investigation,
to provide information on the Year 2000 date issue as it relates
to medical devices.
- Susan S. Ellenberg, Ph.D., May
18, 1999
Director, Biostatistics & Epidemiology Division, CBER of the
Food and Drug Administration before the Subcommittee on Criminal
Justice, Drug Policy and Human Resources, to discuss the Vaccine
Adverse Event Reporting System (VAERS), designed to receive
and evaluate reports of adverse events following vaccinations.
April
- Kathryn C. Zoon, Ph.D.,
April 29, 1999
Director, Center for Biologics Evaluation and Research of
the Food and Drug Administration before the Subcommittee on
National Security, Veterans Affair and International Relations,
to discuss the safety and efficacy of the anthrax vaccine.
- Thomas Shope, M.D., April
20, 1999
Special Assistant to the Director, Office of Science and Technology,
Center for Devices and Radiological Health of the Food and
Drug Administration before the Committee on Veterans' Affairs,
to provide information on the Year 2000 date issue as it relates
to medical devices.
- William K. Hubbard, April
15, 1999
Acting Deputy Commissioner for Policy of the Food and Drug
Administration before the Subcommittee on Oversight and Investigation,
to provide information on the Year 2000 date issue as it relates
to medical devices and pharmaceuticals.
March
- Jane Henney, M.D., March 25,
1999
Commissioner of Food and Drug Administration before the Committee
of Government Reform, to discuss of implementation of the
Dietary Supplement Health and Education Act (DSHEA) of 1994.
- Elizabeth D. Jacobson,
Ph.D., March 25, 1999
Acting Director Center for Devices and Radiological Health
of the Food and Drug Administration before the Committee on
Education and the Workforce, to discuss issues related to
the regulation of natural rubber latex gloves.
- Jane Henney, M.D., March 16,
1999
Commissioner of Food and Drug Administration before the Committee
on Appropriations, to discuss the highlights of the Agency's
food safety accomplishments for fiscal 1998, the plans for
fiscal year 1999 and the expectations for food safety with
the proposed budget for fiscal year 2000.
- Nicholas Reuter, MPH, March
11, 1999
Associate Director for Domestic and International Drug Control,
Office of Health Affairs before the Subcommittee on Oversight
and Invetigations Committee on Commerce, testified on the
role of the Food and Drug Administration (FDA or Agency) in
the scheduling of drugs under the Controlled Substances Act
(CSA), 21 U.S.C. § 811.
|
![](https://webarchive.library.unt.edu/eot2008/20081004033909im_/http://www.fda.gov/graphics/dot_clear.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081004033909im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
![](https://webarchive.library.unt.edu/eot2008/20081004033909im_/http://www.fda.gov/graphics/dot_clear.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081004033909im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081004033909im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
![](https://webarchive.library.unt.edu/eot2008/20081004033909im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
|
|